In a recent Phase II clinical trial, inhibition of TGF-β expression by OT-101, an anti-sense to TGF-β1, has been shown to suppress SARS-COV and SARS-COV-2 replication and allow patients to recover without going into respiratory crisis 169, suggesting that COVID-19 can be treated with TGF-β inhibition. Here, TGFB1 is linked to COVID-19.